News
Cantor Fitzgerald Reiterates Overweight on Cabaletta Bio, Maintains $50 Price Target
5 Apr 24
News, Price Target, Reiteration, Analyst Ratings
Citigroup Maintains Buy on Cabaletta Bio, Raises Price Target to $30
4 Apr 24
News, Price Target, Analyst Ratings
Cabaletta Bio Issued ID#NCT06328777 For Phase 1/2 Open-Label Study To Evaluate The Safety And Efficacy Of CABA-201, A CD19-CAR T Cell Therapy, In Subjects With Systemic Sclerosis Posted To Clinical Trials Website On 2024-03-25; Study Is Not Yet Recruiting
25 Mar 24
Biotech, News, General
Cantor Fitzgerald Reiterates Overweight on Cabaletta Bio, Maintains $50 Price Target
22 Mar 24
News, Price Target, Reiteration, Analyst Ratings
Wells Fargo Maintains Overweight on Cabaletta Bio, Raises Price Target to $35
22 Mar 24
News, Price Target, Analyst Ratings
HC Wainwright & Co. Maintains Buy on Cabaletta Bio, Raises Price Target to $30
22 Mar 24
News, Price Target, Analyst Ratings
Recap: Cabaletta Bio Q4 Earnings
21 Mar 24
Earnings
Cabaletta Bio Q4 EPS $(0.46) Misses $(0.39) Estimate; Cabaletta Had Cash, Cash Equivalents And Short-term Investments Of $241.2M Expected To Fund Its Operating Plan Into The First Half Of 2026
21 Mar 24
Earnings, News
Cramer: This REIT Is 'A Little Too Dicey'; As For Marathon Digital, 'Own The Pure'
6 Mar 24
Long Ideas, News, Small Cap, Top Stories, Markets, Media, Trading Ideas
Jefferies Initiates Coverage On Cabaletta Bio with Buy Rating, Announces Price Target of $36
5 Feb 24
News, Price Target, Initiation, Analyst Ratings